Clinical advances in hematology & oncology : H&O

Keyphrases

Publications

volume 21, number 3, 2023

Karen M Yun, Lyudmila Bazhenova
Management of toxicities associated with immune checkpoint inhibitors. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Sapna P Patel
New evidence for neoadjuvant therapy in advanced melanoma. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Erika P Hamilton
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Andrew D Zelenetz
Zandelisib and B-cell lymphomas. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Leonard Saltz
Factors guiding selection of treatment in metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Andrew D Zelenetz
Zandelisib and B-cell lymphomas. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Leonard Saltz
Factors guiding selection of treatment in metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Lorenzo Iovino, Mazyar Shadman
CAR T-cell therapy for CLL: a new addition to our treatment toolbox? Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Erika P Hamilton
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Leonard Saltz
Factors guiding selection of treatment in metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Jae Y Kim
The use of biomarkers in early-stage NSCLC. Clinical advances in hematology & oncology : H&O 21 (3) (2023)
Jae Y Kim
The use of biomarkers in early-stage NSCLC. Clinical advances in hematology & oncology : H&O 21 (3) (2023)

volume 21, number 4, 2023

Forat Lutfi, Ameet Patel, Jasmine Mehta, Anmol Goyal, Saurabh Dahiya
Second-line treatment with CAR T-cell therapy for large B-cell lymphoma. Clinical advances in hematology & oncology : H&O 21 (4) (2023)
Ian W Flinn
Is there still a role for PI3K inhibitors in CLL? Clinical advances in hematology & oncology : H&O 21 (4) (2023)
Christopher E Wee, Timothy D Gilligan
Management of testicular germ cell tumors. Clinical advances in hematology & oncology : H&O 21 (4) (2023)
Sunnie Kim
The role of antiangiogenesis agents in refractory metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O 21 (4) (2023)
Lucia Masarova
Momelotinib, the next JAK2 inhibitor? Clinical advances in hematology & oncology : H&O 21 (4) (2023)
Garth W Strohbehn
New strategies for dose optimization in oncology: insights from targeted small-molecule therapies for metastatic or advanced non-small cell lung cancer. Clinical advances in hematology & oncology : H&O 21 (4) (2023)
Bhavana Pothuri
Update on strategies for platinum-resistant ovarian cancer. Clinical advances in hematology & oncology : H&O 21 (4) (2023)

volume 21, number 5, 2023

Kathryn T Maples, Sara A Scott, Sagar Lonial
Novel approaches to the treatment of multiple myeloma. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Jorge Cortes
Quizartinib, the next FLT3 inhibitor. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Debra L Richardson
The emerging use of antibody-drug conjugates in ovarian cancer. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Vanita Noronha
Dosing of nivolumab in India. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Jorge Cortes
Quizartinib, the next FLT3 inhibitor. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Naveen Pemmaraju, Hagop Kantarjian
Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Debra L Richardson
The emerging use of antibody-drug conjugates in ovarian cancer. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Vanita Noronha
Dosing of nivolumab in India. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Ingrid Pabinger-Fasching
Management of antithrombin deficiency. Clinical advances in hematology & oncology : H&O 21 (5) (2023)
Ingrid Pabinger-Fasching
Management of antithrombin deficiency. Clinical advances in hematology & oncology : H&O 21 (5) (2023)

volume 21, number 6, 2023

Michael B Atkins
Update on the DREAMseq trial in melanoma. Clinical advances in hematology & oncology : H&O 21 (6) (2023)
Lindsey Roeker
Managing CLL that has progressed after BTK inhibition. Clinical advances in hematology & oncology : H&O 21 (6) (2023)
Raisa Epistola, Joseph Chao, Jennifer Lee
Evolving landscape of targeted treatment options for HER2-positive gastric/gastroesophageal adenocarcinomas. Clinical advances in hematology & oncology : H&O 21 (6) (2023)
Chinmay Jani, Nour Abdallah, Pavlina Chrysafi, Christian Mouchati, Daniel Herchenhorn, Rana R McKay
New drug approvals in prostate cancer and their effect on the treatment landscape. Clinical advances in hematology & oncology : H&O 21 (6) (2023)
Kevin Kalinsky
Advances in SERDs and other novel endocrine therapies. Clinical advances in hematology & oncology : H&O 21 (6) (2023)
Selina M Luger
Is blinatumomab now standard of care consolidation for patients with ALL? Clinical advances in hematology & oncology : H&O 21 (6) (2023)

volume 21, number 7, 2023

Hope S Rugo
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: breast cancer. Clinical advances in hematology & oncology : H&O 21 (7) (2023)
Edward S Kim
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: lung cancer. Clinical advances in hematology & oncology : H&O 21 (7) (2023)
Susan O'Brien
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: leukemia and lymphoma. Clinical advances in hematology & oncology : H&O 21 (7) (2023)
Daniel J George
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: genitourinary cancer. Clinical advances in hematology & oncology : H&O 21 (7) (2023)
Robert L Coleman
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: gynecologic cancer. Clinical advances in hematology & oncology : H&O 21 (7) (2023)

volume 21, number 8, 2023

Matthew C Perez, Jane L Messina, Lilit Karapetyan, Rogerio I Neves, Vernon K Sondak
Acral melanoma: clinical advances and hope for the future. Clinical advances in hematology & oncology : H&O 21 (8) (2023)
Matthew S Davids
Management of Richter transformation. Clinical advances in hematology & oncology : H&O 21 (8) (2023)
Jacob Sands
Updates in small cell lung cancer. Clinical advances in hematology & oncology : H&O 21 (8) (2023)
Gabe S Sonke
Novel sources of funding for clinical trials in oncology. Clinical advances in hematology & oncology : H&O 21 (8) (2023)
Jonathon B Cohen
Recent approval of pirtobrutinib for mantle cell lymphoma. Clinical advances in hematology & oncology : H&O 21 (8) (2023)
Merrick I Ross
Adjuvant therapy in high-risk, node-negative melanoma. Clinical advances in hematology & oncology : H&O 21 (8) (2023)

volume 21, number 9, 2023

Tira Tan
Expanding the use of PARP inhibitors in breast cancer. Clinical advances in hematology & oncology : H&O 21 (9) (2023)
Janice Staber
Principles of gene therapy for the hematologist. Clinical advances in hematology & oncology : H&O 21 (9) (2023)
Susanna Kim, James R Berenson
Predicting outcomes and monitoring disease in patients with multiple myeloma. Clinical advances in hematology & oncology : H&O 21 (9) (2023)
Luca F Valle, Amar U Kishan, Antonio Franco, Ting Martin Ma, John Nikitas, Matthew Farrell, Albert J Chang, Nicholas G Nickols, Michael L Steinberg
Selecting the optimal radiation modality in prostate cancer. Clinical advances in hematology & oncology : H&O 21 (9) (2023)